We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,091.00 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,347 | 21:42:13 |
From Jul 2021 to Jul 2024
By Matt Grossman
Regeneron Pharmaceuticals Inc.'s antibody cocktail for treating Covid-19 generated sales of about $5.82 billion in the U.S. in 2021, Regeneron estimated on Monday.
The Tarrytown, N.Y.-based pharmaceutical company said the preliminary sales figure was based on unaudited fourth-quarter sales of about $2.29 billion for the therapy. Regeneron released the estimate ahead of its appearance at an industry conference later Monday.
Regeneron also estimated that its Eylea injection, used to treat age-related macular degeneration and other eye conditions, accounted for U.S. sales of about $5.79 billion. In the fourth quarter, Eylea sales were about $1.54 billion, Regeneron said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
January 10, 2022 06:39 ET (11:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
